Scarica l'app Stockscreener
16.86
3.27%
-0.57
Dopo l'orario di chiusura:
16.86
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Eyepoint Inc Borsa (EYPT) Ultime notizie
Can EyePoint Pharmaceuticals Inc. stock maintain growth trajectory2026 world cup usa national team group stage star players transition play group prediction guide - Улправда
Is EyePoint Pharmaceuticals the Next Sleeper Stock Legend or Just Overhyped Noise? - AD HOC NEWS
EyePoint (EYPT) price target increased by 10.87% to 36.80 - MSN
What drives EyePoint Pharmaceuticals Inc PV3B stock priceSell Signals and Alerts & Top Analyst Picks Available for Free - earlytimes.in
Eyepoint Pharmaceuticals (NASDAQ:EYPT) Trading Down 6.1%Here's What Happened - MarketBeat
The Year-End 2025 Biotech Rally And What It Means For 2026 - Benzinga
Understanding the Setup: (EYPT) and Scalable Risk - Stock Traders Daily
Eyepoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Given Average Recommendation of "Buy" by Analysts - MarketBeat
EyePoint, Inc.Common Stock (Nasdaq:EYPT) Stock Quote - FinancialContent
127,489 Shares in Eyepoint Pharmaceuticals, Inc. $EYPT Purchased by Corient Private Wealth LLC - MarketBeat
Why EyePoint (EYPT) Is Up 9.6% After Upbeat Earnings Revisions And Momentum SignalsAnd What's Next - Sahm
EyePoint (EYPT): Assessing Valuation After Earnings Upgrades and Strong Momentum-Driven Share Gains - Yahoo Finance
Eyepoint Pharmaceuticals (NASDAQ:EYPT) Stock Price Down 6.2%Time to Sell? - MarketBeat
EyePoint Earnings Notes - Trefis
EyePoint (EYPT) Is Up 9.01% in One Week: What You Should Know - Yahoo Finance
3 Biotech Stocks Wall Street Analysts Are Bullish on for 2026 - Zacks Investment Research
Will EyePoint Pharmaceuticals Inc. stock rally after Fed decisionsWeekly Risk Summary & Technical Analysis for Trade Confirmation - Улправда
EyePoint (EYPT) Price Target Increased by 10.87% to 36.80 - Nasdaq
Is EyePoint Pharmaceuticals Inc. stock dividend yield sustainable2025 Technical Overview & Expert Approved Momentum Ideas - Улправда
Eyepoint Pharmaceuticals (NASDAQ:EYPT) Rating Increased to Strong-Buy at TD Cowen - MarketBeat
Why (EYPT) Price Action Is Critical for Tactical Trading - news.stocktradersdaily.com
Can EyePoint Pharmaceuticals Inc. stock resist market sell offsMarket Risk Summary & High Conviction Buy Zone Picks - Улправда
Will EyePoint Pharmaceuticals Inc. stock continue dividend increases2025 Short Interest & Step-by-Step Swing Trade Plans - Улправда
Is EyePoint Pharmaceuticals Inc a good long term investmentOptions Trading Strategies & Free Tap Rapid Wealth - earlytimes.in
How sustainable is EyePoint Pharmaceuticals Inc. stock dividend payoutMarket Sentiment Review & Precise Trade Entry Recommendations - DonanımHaber
Is EyePoint Pharmaceuticals Inc. stock overvalued by current metricsPortfolio Value Report & Weekly High Conviction Trade Ideas - Улправда
Will EyePoint Pharmaceuticals Inc. stock reach all time highs in 2025 - DonanımHaber
Inflation Data: How EyePoint Pharmaceuticals Inc. (PV3B) stock compares with market leadersJuly 2025 Sentiment & Community Trade Idea Sharing Platform - Улправда
How EyePoint Pharmaceuticals Inc. stock reacts to oil pricesWeekly Stock Recap & Expert Approved Trade Ideas - DonanımHaber
Should I hold or sell EyePoint Pharmaceuticals Inc. stock in 2025July 2025 Rallies & Low Risk Growth Stock Ideas - Улправда
Support Test: Will EyePoint Pharmaceuticals Inc. stock see PE expansionDividend Hike & Low Risk Entry Point Guides - Улправда
EyePoint to Present at the 44th Annual J.P. Morgan Healthcare Conference - The Globe and Mail
EyePoint, Inc. CEO Jay S. Duker to Present at 44th Annual J.P. Morgan Healthcare Conference - Quiver Quantitative
Eye disease drug developer to present at major healthcare conf - Stock Titan
EyePoint (STU:PV3B) OCF Margin % : -6,144.59% (As of Sep. 2025) - GuruFocus
EyePoint reports inducement grants under NASDAQ listing rule - MSN
Eyepoint Pharmaceuticals (NASDAQ:EYPT) Trading 5.8% HigherWhat's Next? - MarketBeat
EyePoint (EYPT) Grants Stock Options to New Employees as Inducem - GuruFocus
Eyepoint reports inducement grants under Nasdaq listing rule - marketscreener.com
Eyepoint Reports Inducement Grants Under NASDAQ Listing Rule - TradingView — Track All Markets
EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - GlobeNewswire
Buy Recommendation for EyePoint Pharmaceuticals: Strong Clinical Positioning and Market Potential of Duravyu in Wet AMD - TipRanks
Certain Pre-Funded Warrants of EyePoint, Inc. are subject to a Lock-Up Agreement Ending on 14-DEC-2025. - marketscreener.com
Certain Stock Options of EyePoint, Inc. are subject to a Lock-Up Agreement Ending on 14-DEC-2025. - marketscreener.com
68,889,649 Common Stock of EyePoint, Inc. are subject to a Lock-Up Agreement Ending on 14-DEC-2025. - marketscreener.com
Cormorant Asset Management Reduces Stake in EyePoint Pharmaceuti - GuruFocus
After Leaping 38% EyePoint, Inc. (NASDAQ:EYPT) Shares Are Not Flying Under The Radar - simplywall.st
EyePoint, Inc.: Dividend historical data and projections - marketscreener.com
Update Report: Is EyePoint Pharmaceuticals Inc stock positioned for long term growth2025 Biggest Moves & High Accuracy Swing Trade Signals - moha.gov.vn
Stempoint Capital LP Acquires New Position in Eyepoint Pharmaceuticals, Inc. $EYPT - MarketBeat
EyePoint stock maintains Outperform rating at Mizuho amid competitor moves By Investing.com - Investing.com Australia
EyePoint stock maintains Outperform rating at Mizuho amid competitor moves - Investing.com India
EyePoint Pharmaceuticals (EYPT) Maintains Positive Outlook Amid Competitive Dynamics - GuruFocus
Walleye Capital LLC Has $1.88 Million Position in Eyepoint Pharmaceuticals, Inc. $EYPT - MarketBeat
EyePoint (EYPT) Is Up 25.0% After DURAVYU Phase 3 Safety Green Light And $200M ATM Offering - simplywall.st
2.52%
0.07%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):